Role of SGLT2I in Patients With Myocardial Infarction

Recruiting

• Conditions: Diabetes Mellitus; Myocardial Infarction
• Interventions: Drug: SGLT2 inhibitor

• Registration Number: NCT06245980
• Lead Sponsor: Dongying Zhang

Brief Summary

Role of sglt2I in diabetic patients with myocardial infarction

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-01
• Status Verified: 2023-05
• Study First Submitted: 2024-01-30
• Study First Submitted QC: 2024-01-30
• Study First Posted: 2024-02-07
• Last Update Submitted: 2024-02-07
• Last Update Posted: 2024-02-08
• Primary Completion: 2024-02-28
• Study Completion: 2024-03-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1200

Inclusion Criteria

1. Acute myocardial infarction patients
2. Type 2 diabetics.

Exclusion Criteria

1. Patients undergoing coronary artery bypass grafting (CABG).
2. Severe valvular heart disease.
3. Contraindications of secondary medical preventive therapy for myocardial infarction, such as β-blockers, angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin-converting enzyme inhibitors (ARBs), antiplatelets, and statins.
4. Previously used SGLT2i.
5. Severe hepatic and renal insufficiency.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
With SGLT2I	SGLT2 inhibitor	-

Primary Outcome Measures

Name	Time	Method
Heart failure readmission	24months	Heart failure readmission
MACE	24months	cardiovascular death and heart failure and myocardial infarction

Secondary Outcome Measures

Name	Time	Method
cardiovascular death	24months	cardiovascular death
Recurrent myocardial infarction	24months	Recurrent myocardial infarction

Trial Locations

Locations (1)

The First Affiliated Hospital of Chongqing Medical University; 🇨🇳 Chongqing, Chongqing, China